Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  apoptosis induction therapy, apoptosis-targeted therapy
Results 1-24 of 24 for your search:
Start Over
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: C16014, NCI-2013-01188, 163325, 2013-000326-54, U1111-1158-2646, NCT01850524
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 months and under
Trial IDs: ANBL1232, NCI-2014-00677, NCT02176967
A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BO25323, NCI-2015-00926, 2014-001810-24, NCT02242942
Lenalidomide and AT-101 in Treating Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MC128A, NCI-2009-01569, NCT01021345, NCT01003769
Smac Mimetic TL32711 in Treating Older Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome, or Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: UPCC 15411, NCI-2011-03720, NCT01486784
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MC1125, NCI-2012-00518, 11-001987, NCT01737502
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0986, NCI-2010-02326, 10-004705, CLBH589BUS59T, NCT01261247
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin in Treating Patients With High-Risk Neuroblastoma Previously Treated With High-Dose Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 8 and under
Trial IDs: DIV-NB-201, NCI-2012-01336, CDR0000733747, 9347, NCT01592045
Chemotherapy and R-(-)-Gossypol Acetic Acid in Preserving the Larynx in Patients With Stage III or IV Laryngeal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HUM00043975, NCI-2012-01021, CR00040536, HUM 43975, UMCC 2010.101, NCT01633541
Digoxin in Treating Patients With Stage I-III Breast Cancer Planning to Undergo Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: SKCCC J1232, NCI-2013-00513, A-17427, J1232, NA_00072292, NCT01763931
SMAC Mimetic LCL161 Alone or with Cyclophosphamide in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1381, NCI-2013-01276, CLCL161AUS01T, NCT01955434
LCL161 in Treating Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0612, NCI-2014-01241, CLCL161AUS02T, NCT02098161
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TL32711-RAN-0094-PTL, NCI-2014-01549, 2014-001719-37, TL32711-0094, NCT02147873
Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SOR-C13 01, NCI-2014-01152, NCT01578564
Dexanabinol in Treating Patients With Recurrent Brain Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SK01-ETS2101, NCI-2012-01204, 111827, NCT01654497
Trametinib and Digoxin in Treating Patients with Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: SCCC-01614, NCI-2014-01177, 012014-007, 8843, Mod4_STU 012014-007, NCT02138292
Sodium Selenite and Radiation Therapy in Treating Patients with Metastatic Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PROS0047, NCI-2014-01361, 30587, 4593, IRB-30587, NCT02184533
Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: M14-358, NCI-2014-01763, 2014-000687-18, NCT02203773
Start Over